Related Experiment Video
Updated: Dec 24, 2025
03:53
Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
Published on: April 19, 2024
974
Bronchiectasis in Primary Antibody Deficiencies: A Multidisciplinary Approach.
Luke A Wall1,2, Elizabeth L Wisner1,2, Kevin S Gipson3
1Division of Allergy Immunology, Department of Pediatrics, Louisiana State University Health Sciences Center New Orleans, New Orleans, LA, United States.
Frontiers in Immunology
|April 17, 2020
Summary
Bronchiectasis, a lung condition, is a serious complication of primary antibody deficiencies. Early identification and a multidisciplinary approach are crucial for managing lung damage and improving quality of life.
Area of Science:
- Pulmonology
- Immunology
- Clinical Medicine
Background:
- Bronchiectasis, characterized by bronchial wall thickening and airway dilatation, is a significant complication in primary antibody deficiencies.
- Infections are a primary driver, but bronchiectasis can develop independently, initiating a progressive cycle of lung damage.
- Untreated bronchiectasis leads to severe symptoms, reduced quality of life, and increased mortality.
Purpose of the Study:
- To review the identification and management of bronchiectasis in patients with primary antibody deficiencies.
- To emphasize the need for combined immunology and pulmonary perspectives in treatment.
- To advocate for an aggressive, multidisciplinary approach to mitigate disease progression.
Main Methods:
- This is a review article synthesizing current knowledge.
- It integrates expertise from immunology and pulmonology specialists.
- Focuses on diagnostic and therapeutic strategies.
Main Results:
- Bronchiectasis in primary antibody deficiencies requires integrated management.
- A multidisciplinary approach is key to reducing exacerbations.
- Early intervention can slow the progression of permanent lung damage.
Conclusions:
- Effective management of bronchiectasis in primary antibody deficiencies necessitates a combined approach.
- Addressing both the immune deficiency and the bronchiectasis is critical.
- Aggressive, multidisciplinary care can significantly improve patient outcomes and slow disease progression.
Related Concept Videos
01:20Asthma: Pathogenesis and Management
1.1K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.1K
01:28Pulmonary Tuberculosis V
473
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
473
01:24Cystic Fibrosis: Management
378
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
378
01:28Pleural Effusion II: Symptoms and Management
509
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
509
01:30Asthma-IV: Diagnostic and Management
3.0K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.0K
01:26COPD: Management Using Bronchodilators and Corticosteroids
643
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
643